CDC Public Access to Publications

CDC Public Access to Publications

CDC Stacks Public Health Publications

This is the CDC Stacks Public Access to Publications Page.

Morbidity and Mortality Weekly Report (MMWR) Morbidity and Mortality Weekly Report (MMWR)

Morbidity and Mortality Weekly Report (MMWR)

The Morbidity and Mortality Weekly Report (MMWR) series are CDC’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. The MMWR series includes the following publications: MMWR Weekly, MMWR Recommendations and Reports, CDC Surveillance Summaries and MMWR Supplements. These journals are freely available to the public as Diamond Open Access. For more on MMWR, visit https://www.cdc.gov/mmwr/index.html.

Narrow Results:
Volume
Series
Publication Year
Medical Subject
Personal Author
  • x
    Murthy, Kempapura (24)
Corporate Author
Place as Subject
Resource Type General
x Murthy, Kempapura
  • Early Estimates of Seasonal Influenza Vaccine Effectiveness  United States January 2013
    Early Estimates of Seasonal Influenza Vaccine Effectiveness — United States, January 2013
    :
    :
  • Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness  United States February 2013
    Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness — United States, February 2013
    :
    :
  • Interim Estimates of 201617 Seasonal Influenza Vaccine Effectiveness  United States February 2017
    Interim Estimates of 2016–17 Seasonal Influenza Vaccine Effectiveness — United States, February 2017
    :
    :
  • Interim Estimates of 201718 Seasonal Influenza Vaccine Effectiveness  United States February 2018
    Interim Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness — United States, February 2018
    :
    :
  • Effectiveness of PfizerBioNTech and Moderna Vaccines Against COVID19 Among Hospitalized Adults Aged 65 Years  United States JanuaryMarch 2021
    Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
    :
    :
  • Laboratoryconfirmed COVID19 Among Adults Hospitalized with COVID19like Illness with Infectioninduced or MRNA Vaccineinduced SARSCoV2 Immunity  Nine States JanuarySeptember 2021
    Laboratory-confirmed COVID-19 Among Adults Hospitalized with COVID-19–like Illness with Infection-induced or MRNA Vaccine-induced SARS-CoV-2 Immunity — Nine States, January–September 2021
    :
    :
  • Effectiveness of 2dose Vaccination with MRNA COVID19 Vaccines Against COVID19associated Hospitalizations Among Immunocompromised Adults  Nine States JanuarySeptember 2021
    Effectiveness of 2-dose Vaccination with MRNA COVID-19 Vaccines Against COVID-19–associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021
    :
    :
  • Effectiveness of PfizerBioNTech and Moderna Vaccines Against COVID19 Among Hospitalized Adults Aged 65 Years  United States JanuaryMarch 2021
    Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
    :
    :
  • Sustained Effectiveness of PfizerBioNTech and Moderna Vaccines Against COVID19 Associated Hospitalizations Among Adults  United States MarchJuly 2021
    Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
    :
    :
  • Comparative Effectiveness of Moderna PfizerBioNTech and Janssen Johnson  Johnson Vaccines in Preventing COVID19 Hospitalizations Among Adults Without Immunocompromising Conditions  United States MarchAugust 2021
    Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
    :
    :
  • LaboratoryConfirmed COVID19 Among Adults Hospitalized with COVID19Like Illness with InfectionInduced or mRNA VaccineInduced SARSCoV2 Immunity  Nine States JanuarySeptember 2021
    Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021
    :
    :
  • Effectiveness of 2Dose Vaccination with mRNA COVID19 Vaccines Against COVID19Associated Hospitalizations Among Immunocompromised Adults  Nine States JanuarySeptember 2021
    Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021
    :
    :
  • Waning 2dose and 3dose Effectiveness of MRNA Vaccines Against COVID19associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variants Predominance  VISION Network 10 States August 2021January 2022
    Waning 2-dose and 3-dose Effectiveness of MRNA Vaccines Against COVID-19–associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variants Predominance — VISION Network, 10 States, August 2021–January 2022
    :
    :
  • Effectiveness of a Third Dose of MRNA Vaccines Against COVID19associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variants Predominance  VISION Network 10 States August 2021January 2022
    Effectiveness of a Third Dose of MRNA Vaccines Against COVID-19–associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variants Predominance — VISION Network, 10 States, August 2021–January 2022
    :
    :
  • Effectiveness of COVID19 PfizerBioNTech BNT162b2 MRNA Vaccination in Preventing COVID19associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 517 Years  VISION Network 10 States April 2021January 2022
    Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 MRNA Vaccination in Preventing COVID-19–associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
    :
    :
  • Effectiveness of 2 3 and 4 COVID19 MRNA Vaccine Doses Among Immunocompetent Adults During Periods When SARSCoV2 Omicron BA1 and BA2BA2121 Sublineages Predominated  VISION Network 10 States
    Effectiveness of 2, 3, and 4 COVID-19 MRNA Vaccine Doses Among Immunocompetent Adults During Periods When SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States
    :
    :
  • Effectiveness of a Third Dose of PfizerBioNTech and Moderna Vaccines in Preventing COVID19 Hospitalization Among Immunocompetent and Immunocompromised Adults  United States AugustDecember 2021
    Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021
    :
    :
  • Effectiveness of a Third Dose of mRNA Vaccines Against COVID19Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance  VISION Network 10 States August 2021January 2022
    Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
    :
    :
  • Waning 2Dose and 3Dose Effectiveness of mRNA Vaccines Against COVID19Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance  VISION Network 10 States August 2021January 2022
    Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
    :
    :
  • Effectiveness of COVID19 PfizerBioNTech BNT162b2 mRNA Vaccination in Preventing COVID19Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 517 Years  VISION Network 10 States April 2021January 2022
    Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
    :
    :
1 - 20 / 24
Sort By: